Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says
Executive Summary
FDA calls off November meeting to give 'more time to review and resolve several outstanding issues' with adjuvanted hepatitis B vaccine; Dynavax says agency determined meeting was not necessary to ensure regulatory decision by Dec. 15 goal date.